DK0686162T3 - Forbedret fremgangsmåde til refoldning af proteiner - Google Patents
Forbedret fremgangsmåde til refoldning af proteinerInfo
- Publication number
- DK0686162T3 DK0686162T3 DK94906891T DK94906891T DK0686162T3 DK 0686162 T3 DK0686162 T3 DK 0686162T3 DK 94906891 T DK94906891 T DK 94906891T DK 94906891 T DK94906891 T DK 94906891T DK 0686162 T3 DK0686162 T3 DK 0686162T3
- Authority
- DK
- Denmark
- Prior art keywords
- proteins
- factor
- recognition sites
- novel
- correctly folded
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000030788 protein refolding Effects 0.000 title 1
- 108010074860 Factor Xa Proteins 0.000 abstract 4
- 235000018102 proteins Nutrition 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 108010022999 Serine Proteases Proteins 0.000 abstract 1
- 102000012479 Serine Proteases Human genes 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 238000001212 derivatisation Methods 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 210000003000 inclusion body Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 238000004153 renaturation Methods 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
- C12N2310/1241—Tetrahymena
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK13093A DK13093D0 (da) | 1993-02-04 | 1993-02-04 | Processing of proteins |
DK13993A DK13993D0 (da) | 1993-02-05 | 1993-02-05 | Processing of proteins |
PCT/GB1993/002492 WO1994013804A1 (fr) | 1992-12-04 | 1993-12-03 | Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation |
PCT/DK1994/000054 WO1994018227A2 (fr) | 1993-02-04 | 1994-02-04 | Procede ameliore de repliement de proteines |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0686162T3 true DK0686162T3 (da) | 2003-09-22 |
Family
ID=26063372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK94906891T DK0686162T3 (da) | 1993-02-04 | 1994-02-04 | Forbedret fremgangsmåde til refoldning af proteiner |
Country Status (14)
Country | Link |
---|---|
US (2) | US5739281A (fr) |
EP (1) | EP0686162B1 (fr) |
JP (1) | JP3695467B2 (fr) |
KR (1) | KR100310739B1 (fr) |
AT (1) | ATE241642T1 (fr) |
AU (1) | AU674568B2 (fr) |
CA (1) | CA2155335C (fr) |
DE (1) | DE69432744T2 (fr) |
DK (1) | DK0686162T3 (fr) |
ES (1) | ES2199959T3 (fr) |
FI (1) | FI113272B (fr) |
NO (1) | NO316274B1 (fr) |
NZ (1) | NZ261571A (fr) |
WO (1) | WO1994018227A2 (fr) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU674568B2 (en) * | 1993-02-04 | 1997-01-02 | Anaphore, Inc. | Improved method for the refolding of proteins |
WO1997000886A1 (fr) * | 1995-06-22 | 1997-01-09 | Eli Lilly And Company | Intermediaires de proteines contre l'obesite, leur preparation et leur utilisation |
US7368111B2 (en) | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
AU703145B2 (en) * | 1995-11-07 | 1999-03-18 | Toshio Tanaka | Method for expression cloning of gene encoding ligand-bound protein |
DE59711957D1 (de) * | 1996-06-11 | 2004-10-28 | Roche Diagnostics Gmbh | Rekombinante blutgerinnungsproteasen |
EP1012280B1 (fr) | 1997-06-11 | 2004-11-10 | Borean Pharma A/S | Module formant des trimeres |
US20030207402A1 (en) * | 1997-08-22 | 2003-11-06 | Erhard Kopetzki | Autocatalytically activatable zymogenic precursors of proteases and their use |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
WO2001079481A2 (fr) * | 2000-04-17 | 2001-10-25 | Dyax Corp. | Nouvelles methodes de construction de bibliotheques de materiels genetiques representant les membres d'une famille diversifiee de peptides, de polypeptides ou de proteines |
AU2001280436A1 (en) * | 2000-07-12 | 2002-01-21 | Eli Lilly And Company | Process to increase protein stability |
AU2001296303A1 (en) * | 2000-09-22 | 2002-04-02 | Ramot At Tel Aviv University Ltd. | A soluble beta 2 microglobulin (beta2m)/hfe monochain for biotechnological and therapeutic applications |
CN1268641C (zh) | 2000-11-10 | 2006-08-09 | 普罗蒂奥制药公司 | 载脂蛋白类似物 |
US20040132094A1 (en) | 2000-12-13 | 2004-07-08 | Michael Etzerodt | Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains |
NZ526312A (en) | 2000-12-13 | 2004-11-26 | Borean Pharma As | Combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains |
ES2360479T3 (es) | 2000-12-18 | 2011-06-06 | Dyax Corp. | Bibliotecas focalizadas de paquetes genéticos. |
US20060252917A1 (en) * | 2001-02-08 | 2006-11-09 | University Of Utah | Methods for refolding conformationally constrained peptides |
DE10105912A1 (de) * | 2001-02-09 | 2002-08-14 | Roche Diagnostics Gmbh | Rekombinante Proteinase K |
AU2003249014B2 (en) * | 2002-07-09 | 2009-07-02 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP1382614A1 (fr) * | 2002-07-15 | 2004-01-21 | Bayer HealthCare AG | Procédé de purification de l'interleukine-4 et ses muteines |
US20040067532A1 (en) * | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
US20040072262A1 (en) * | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
CN101899106A (zh) | 2002-10-29 | 2010-12-01 | 阿纳福公司 | 三聚细胞因子的三聚结合蛋白 |
AU2003300785A1 (en) * | 2002-11-12 | 2004-06-03 | Incyte Corporation | Carbohydrate-associated proteins |
JP4833056B2 (ja) | 2003-04-23 | 2011-12-07 | アナフォア インコーポレイテッド | グランザイムbプロテアーゼを使用した融合タンパク質の開裂 |
US20100028995A1 (en) * | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
WO2005094185A2 (fr) * | 2004-03-30 | 2005-10-13 | Sudershan Biotech Limited | Chymosine de veau de recombinaison et procede de fabrication |
CA2584137A1 (fr) * | 2004-10-22 | 2006-06-08 | Amgen Inc. | Methodes de repliement de polypeptides |
CA2646329C (fr) * | 2006-03-20 | 2018-07-03 | The Regents Of The University Of California | Anticorps modifies diriges contre l'antigene de cellules souches prostatiques servant a cibler le cancer |
EP1845103B1 (fr) * | 2006-04-10 | 2015-02-25 | Boehringer Ingelheim RCV GmbH & Co KG | Méthode pour replier une protéine |
EP2197491A4 (fr) | 2007-09-04 | 2011-01-12 | Univ California | Anticorps d'antigène de cellule souche anti-prostate (psca) à haute affinité pour un ciblage et une détection de cancer |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
MX344415B (es) | 2007-09-14 | 2016-12-15 | Adimab Inc | Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos. |
US8324151B2 (en) * | 2007-11-20 | 2012-12-04 | The Feinstein Institute For Medical Research | Treatment of sepsis and septic shock using ghrelin and growth hormone |
US9873957B2 (en) * | 2008-03-13 | 2018-01-23 | Dyax Corp. | Libraries of genetic packages comprising novel HC CDR3 designs |
WO2009132287A2 (fr) * | 2008-04-24 | 2009-10-29 | Dyax Corp. | Bibliothèques de matériels génétiques comprenant de nouvelles conceptions cdr1, cdr2 et cdr3 hc et de nouvelles conceptions cdr1, cdr2 et cdr3 lc |
ES2550384T3 (es) * | 2008-12-18 | 2015-11-06 | Dana-Farber Cancer Institute, Inc. | NKG2D-Fc para la inmunoterapia |
US20110082054A1 (en) * | 2009-09-14 | 2011-04-07 | Dyax Corp. | Libraries of genetic packages comprising novel hc cdr3 designs |
EP2499255A4 (fr) * | 2009-11-09 | 2013-06-19 | Univ Colorado Regents | Production efficace de peptides |
KR102318383B1 (ko) | 2010-07-16 | 2021-10-27 | 아디맵 엘엘씨 | 항체 라이브러리 |
EP2420253A1 (fr) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Synthèse de molécules polyvalentes et multifonctionnelles avec un domaine de trimérisation de collagène XV |
US20150139991A1 (en) | 2010-10-15 | 2015-05-21 | Leadartis, S.L. | Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain |
EP2441776A1 (fr) | 2010-10-15 | 2012-04-18 | Leadartis, S.L. | Génération de complexes polyvalents et multifonctionnels avec un domaine de trimérisation XVIII du collagène |
EP3164417A1 (fr) | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Diabodies hétérodimères bispécifiques et leurs utilisations |
WO2017083612A1 (fr) | 2015-11-13 | 2017-05-18 | Dana-Farber Cancer Institute, Inc. | Protéine de fusion nkg2d-ig pour l'immunothérapie contre le cancer |
US20210246217A1 (en) | 2018-06-06 | 2021-08-12 | Leadartis, S.L. | Trimeric polypeptide complexes and uses thereof |
US20240092942A1 (en) | 2021-03-05 | 2024-03-21 | Leadartis, S.L. | Trimeric polypeptides and uses thereof in the treatment of cancer |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1200773A (fr) * | 1980-02-29 | 1986-02-18 | William J. Rutter | Liens d'expression |
US4444878A (en) * | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
GB2138004B (en) * | 1983-03-25 | 1987-05-13 | Celltech Ltd | A process for the production of a protein |
GB8412517D0 (en) * | 1984-05-16 | 1984-06-20 | Nagai K | Recombinant fusion proteins |
GB8508340D0 (en) * | 1985-03-29 | 1985-05-09 | Creighton T E | Production of protein |
US4656255A (en) * | 1985-09-09 | 1987-04-07 | International Minerals & Chemical Corp. | Protein recovery |
CA1340522C (fr) * | 1987-03-10 | 1999-05-04 | Heinz Dobeli | Proteins hybrides renfermant des histidines voisines pour une purification amelioree |
US5074977A (en) * | 1987-05-05 | 1991-12-24 | The Washington Technology Center | Digital biosensors and method of using same |
US4999422A (en) * | 1988-04-15 | 1991-03-12 | Biogen, N.V. | Continuous method of refolding proteins |
US5231168A (en) * | 1988-09-16 | 1993-07-27 | Statens Seruminstitut | Malaria antigen |
DE3835350A1 (de) * | 1988-10-17 | 1990-04-19 | Boehringer Mannheim Gmbh | Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern |
EP0432419B1 (fr) * | 1989-12-05 | 1994-10-19 | American Cyanamid Company | Méthode de solubilisation et de naturation de la somatotropine utilisant une concentration basse d'urée |
US5324436A (en) * | 1991-12-13 | 1994-06-28 | The Administrators Of The Tulane Educational Fund | Use of hydrate formation to control membrane mimetic systems |
AU674568B2 (en) * | 1993-02-04 | 1997-01-02 | Anaphore, Inc. | Improved method for the refolding of proteins |
-
1994
- 1994-02-04 AU AU60380/94A patent/AU674568B2/en not_active Ceased
- 1994-02-04 CA CA002155335A patent/CA2155335C/fr not_active Expired - Fee Related
- 1994-02-04 EP EP94906891A patent/EP0686162B1/fr not_active Expired - Lifetime
- 1994-02-04 ES ES94906891T patent/ES2199959T3/es not_active Expired - Lifetime
- 1994-02-04 JP JP51754494A patent/JP3695467B2/ja not_active Expired - Fee Related
- 1994-02-04 KR KR1019950703244A patent/KR100310739B1/ko not_active IP Right Cessation
- 1994-02-04 AT AT94906891T patent/ATE241642T1/de active
- 1994-02-04 NZ NZ261571A patent/NZ261571A/en not_active IP Right Cessation
- 1994-02-04 WO PCT/DK1994/000054 patent/WO1994018227A2/fr active IP Right Grant
- 1994-02-04 DK DK94906891T patent/DK0686162T3/da active
- 1994-02-04 DE DE69432744T patent/DE69432744T2/de not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/469,486 patent/US5739281A/en not_active Expired - Lifetime
- 1995-07-28 NO NO19952989A patent/NO316274B1/no not_active IP Right Cessation
- 1995-08-03 FI FI953705A patent/FI113272B/fi not_active IP Right Cessation
- 1995-09-18 US US08/469,658 patent/US5917018A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU6038094A (en) | 1994-08-29 |
WO1994018227A3 (fr) | 1994-10-13 |
DE69432744D1 (de) | 2003-07-03 |
KR960701083A (ko) | 1996-02-24 |
NO952989L (no) | 1995-10-03 |
NZ261571A (en) | 1997-03-24 |
WO1994018227A2 (fr) | 1994-08-18 |
AU674568B2 (en) | 1997-01-02 |
ATE241642T1 (de) | 2003-06-15 |
ES2199959T3 (es) | 2004-03-01 |
KR100310739B1 (ko) | 2002-05-30 |
NO952989D0 (no) | 1995-07-28 |
CA2155335C (fr) | 2001-06-05 |
US5739281A (en) | 1998-04-14 |
DE69432744T2 (de) | 2004-03-25 |
JP3695467B2 (ja) | 2005-09-14 |
NO316274B1 (no) | 2004-01-05 |
EP0686162A1 (fr) | 1995-12-13 |
FI953705A0 (fi) | 1995-08-03 |
US5917018A (en) | 1999-06-29 |
FI953705A (fi) | 1995-08-03 |
EP0686162B1 (fr) | 2003-05-28 |
JPH08506243A (ja) | 1996-07-09 |
FI113272B (fi) | 2004-03-31 |
CA2155335A1 (fr) | 1994-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0686162T3 (da) | Forbedret fremgangsmåde til refoldning af proteiner | |
CY1111322T1 (el) | Προϊοντα υδρολυσης πρωτεϊνων εμπλουτισμενα σε πεπτιδια που εχουν ενα καρβοξυ-τερματικο υπολειμμα προλινης | |
ATE110414T1 (de) | System zur bearbeitung von hefe, welches eine zur bearbeitungsstelle benachbarte negativ geladene aminosäure beeinhaltet. | |
FI961886A0 (fi) | Ihmisen Kunitz-tyyppiset proteaasi-inhibiittorit | |
ES2075155T3 (es) | Separacion enzimatica de una secuencia de una proteina con amino terminal. | |
BG89942A (bg) | Метод за получаване на протеолитични ензими | |
DE3871798D1 (de) | Modifizierter faktor vii/viia. | |
DK0423302T3 (da) | Anvendelse af hidtil ukendte DNA-fragmenter som kodende sekvens for et signalpeptid til sekretion af modne proteiner i rekombinant gær, ekspressionskassetter, transformeret gær og tilsvarende fremgangsmåde til fremstilling af proteiner | |
ATE350470T1 (de) | Durch thrombin spaltbare chimäre proteine | |
WO2001004146A3 (fr) | Polypeptides d'ecarine, polynucleotides codant pour l'ecarine, et procedes d'utilisation associes | |
DK0901526T3 (da) | Cortistatin: neuropeptider, sammensætninger og metoder | |
NO885391D0 (no) | Nye proteolytiske enzymer. | |
WO2001096366A3 (fr) | Inhibiteurs du facteur de coagulation xa | |
DE69125381D1 (de) | Proteinstruktur des pflanzlichen toxins gelonin | |
ES2134834T3 (es) | Procedimiento para escindir proenzimas. | |
DE60126659D1 (de) | Neue protease | |
IL139338A0 (en) | METHOD OF CONTROLLING CLEAVAGE BY OmpT PROTEASE | |
DK0994187T3 (da) | Renin-aktivt stof omfattende humant prorenin og antistoffer mod prorenin-profragmentet | |
ATE310013T1 (de) | Herstellung von n-(n-(3,3-dimethylbutyl)-l-alpha- aspartyl)-l-phenylalanin-1-methylester durch verwendung vom l-alpha-aspartyl-l-phenylalanin-1- methylester als vorläufer | |
DK1605767T3 (da) | Fremgangsmåde til forbedring af kødkvaliteten hos fisk, proteinhydrolysat og fremgangsmåde til fremstilling af et proteinhydrolysat | |
EP0945512A3 (fr) | Sérine protéases |